Findings from a new genome study could enhance current pathology methods in endometrial cancer and help discern types of endometrial tumors.
Sequencing of 57 prostate cancer genomes found that cancer gains a powerful advantage with abrupt intervals of complex, large-scale DNA reshuffling. This process has been dubbed punctuated cancer evolution.
This activity from myCME offers a review of groundbreaking molecular research and novel treatment options for patients with NSCLC.
Is CYP2D6 genotyping for tamoxifen (Nolvadex) sensitivity before use of the drug beneficial?
Mutations in four genes never before associated with colorectal cancer have been found to raise a person's risk for the disease by up to 40%.
A new position statement from the Oncology Nursing Society urges oncology nurses to incorporate new genomic information into practice and patient education.
A new study demonstrated the existence of new fragile genomic sites responsible for chromosomal alterations in tumors.
Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15% of brain tumors known as meningiomas.
A novel genetic anomaly was identified in a 44-year-old woman with solitary fibrous tumor. This anomaly provides an important clue to improving how this cancer is diagnosed and treated.
Abnormal epigenetic changes can change the expression of genes. Researchers hope to control the harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs.
T-cell acute lymphoblastic leukemia (T-ALL) in adults has significantly more mutations than does T-ALL in children, scientists have discovered.
The definition of hormone-sensitive breast tumors known as luminals has been changed by a recent study.
The latest generation of genomic tests for breast cancer can improve physicians' ability to diagnose the disease and more precisely tailor each patient's treatment. This study examined the first commercially available genomic tests.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
A previously invincible mutation in chronic myeloid leukemia has been thwarted by the investigational drug, ponatinib, in a phase I clinical trial.
The ability to detect cancer DNA in the blood has been combined with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.
A small study showed the safety of using gene therapy in the salivary gland to repair damage caused by radiation for head and neck cancer.
A fusion gene that is responsible for 30% of a rare subtype of childhood leukemia with an extremely poor prognosis has been identified. This finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia cases in children.
The first broad genetic landscape map of a Burkitt lymphoma tumor has identified 70 mutations, including several not previously associated with cancer and a new one that is unique to the disease.
Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.
Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.
Two separate research teams identified genes that can predict outcomes in men with castration-resistant prostate cancer (CRPC).
Research into the aggressive behavior of certain adult B-acute lymphoblastic leukemias has yielded a potential new prognostic biomarker and a promising new therapeutic target.
Despite an enormous degree of intercellular heterogeneity in both ductal carcinoma in situ and invasive ductal carcinoma, recurrent patterns of genomic imbalances determine the evolution from noninvasive to invasive disease in most cases.
The basal-like subtype of breast cancer shares many genetic features with high-grade serous ovarian cancer. These findings suggest that these two cancers are of similar molecular origin, so it may facilitate comparing therapeutic data for subtypes of breast and ovarian cancers.
Researchers have identified 12 genetic markers linked with susceptibility for erectile dysfunction after radiotherapy for prostate cancer.
The report found multiple potential therapeutic targets in three case studies, highlighting the need to study the full spectrum of the genome. It also re-emphasizes the need to develop multiple avenues of therapeutics that match the specific medical challenges of each patient.
Melanoma cells are able to build up tolerance to chemotherapy by means of a genetic pathway that inhibits their detection of DNA damage.
PARP inhibitors may be a novel treatment strategy for women with HER2-positive breast cancers, researchers have found.
Many potential targets for squamous cell lung cancer (SCLC) have been identified by The Cancer Genome Atlas (TCGA). The study involved a team of researchers from throughout the United States, plus the British Columbia Cancer Agency in Vancouver, British Columbia, Canada.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|